Lyra Therapeutics Stock (NASDAQ:LYRA)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$7.95

52W Range

$3.81 - $37.50

50D Avg

$10.38

200D Avg

$9.42

Market Cap

$12.47M

Avg Vol (3M)

$707.52K

Beta

0.24

Div Yield

-

LYRA Company Profile


Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

30

IPO Date

May 01, 2020

Website

LYRA Performance


LYRA Financial Summary


Dec 24Dec 23Dec 22
Revenue$1.53M$1.56M$1.36M
Operating Income$-96.35M$-67.12M$-56.31M
Net Income$-93.44M$-62.68M$-55.28M
EBITDA$-96.35M$-65.25M$-53.92M
Basic EPS$-1.43$-1.26$-1.83
Diluted EPS$-1.43$-1.26$-1.83

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts


Q3 21Nov 09, 21 | 4:30 PM
Q2 21Aug 09, 21 | 4:30 PM
Q1 21May 11, 21 | 4:30 PM

Peer Comparison


TickerCompany
RVMDRevolution Medicines, Inc.
CHRSCoherus BioSciences, Inc.
SPROSpero Therapeutics, Inc.
BOLTBolt Biotherapeutics, Inc.
PLRXPliant Therapeutics, Inc.
PASGPassage Bio, Inc.
ORICORIC Pharmaceuticals, Inc.